Thomas J. Herzfeld Advisors’s BeOne Medicines Ltd ONC Stock Holding History

Thomas J. Herzfeld Advisors’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-22	Closed	-$3.96K	–	357
2023 Q3	$3.96K	Hold	22	–	–	﹤0.01%	273
2023 Q2	$3.92K	Hold	22	–	–	﹤0.01%	281
2023 Q1	$4.74K	Buy	22 +7	+47%	+$1.68K	﹤0.01%	234
2022 Q4	$3.3K	Hold	15	–	–	﹤0.01%	273
2022 Q3	$2K	Hold	15	–	–	﹤0.01%	297
2022 Q2	$2K	Hold	15	–	–	﹤0.01%	306
2022 Q1	$3K	Hold	15	–	–	﹤0.01%	295
2021 Q4	$4K	Hold	15	–	–	﹤0.01%	308
2021 Q3	$5K	Hold	15	–	–	﹤0.01%	268
2021 Q2	$5K	Buy	15 +3	+25%	+$994	﹤0.01%	276
2021 Q1	$4K	Buy	12 +1	+9%	+$331	﹤0.01%	288
2020 Q4	$3K	Sell	11 -3	-21%	-$826	﹤0.01%	279
2020 Q3	$4K	Hold	14	–	–	﹤0.01%	211
2020 Q2	$3K	Buy	+14	New	+$2.28K	﹤0.01%	260

Other funds holding ONC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CII

Capital International Inc Los Angeles, California $14.3B AUM 34.19% 1-Year Est. Return

Thomas J. Herzfeld Advisors's ONC Position: Q4 2023 in Review

Thomas J. Herzfeld Advisors sold out of BeOne Medicines Ltd (ONC) in Q4 2023, closing a stake of 22 shares — an estimated $3.96K sold.

Thomas J. Herzfeld Advisors first reported a position in ONC in Q2 2020 and held it in 14 quarters. The position peaked at $5K in Q3 2021. 204 funds tracked by Wall St. Rank hold ONC as of Q4 2023.

Thomas J. Herzfeld Advisors reported no remaining BeOne Medicines Ltd position as of Q4 2023 after selling out during the quarter.
Thomas J. Herzfeld Advisors sold 22 BeOne Medicines Ltd shares in Q4 2023, an estimated $3.96K.
Thomas J. Herzfeld Advisors first reported a position in BeOne Medicines Ltd in Q2 2020 and held it in 14 quarters.
Thomas J. Herzfeld Advisors's BeOne Medicines Ltd position peaked at $5K in Q3 2021.
204 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q4 2023.

Based on Thomas J. Herzfeld Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.